Biography

• Associate Research Fellow, College of Chemistry and Molecular Engineering, Peking University (2021-present)

• Senior Synthetic Chemist, Beijing Chempion Pharmaceuticals.inc. (2019-2020)

• Postdoc, College of Chemistry and Molecular Engineering, Peking University (2015-2019)

• Ph.D., School of Pharmaceutical Sciences, Peking University (2010-2015)

• B.S., Shenyang Pharmaceutical University (2006-2010)

Research Interests

• Targeting Intrinsically Disordered Proteins: Investigating dynamic conformational changes and molecular recognition of IDPs to develop rational drug design methods.

• Targeted Protein Degradation: Developing novel methods for targeted protein degradation to advance drug development for cancer and metabolic disorders.

• Allosteric Drug Design: Developing strategies to overcome drug resistance and enable multifunctional modulation in drug development.

Selected Publications

1. Liu W#, Chen L#, Yin D, Yang Z, Feng J, Sun Q*, Lai L*, Guo X*. Visualizing single-molecule conformational transition and binding dynamics of intrinsically disordered proteins. Nat Commun. 2023, 14(1):5203.

2. Wang L#, Yu Z#, Wang S, Guo Z, Sun Q*, Lai L*. Discovery of novel SARS-CoV-2 3CL protease covalent inhibitors using deep learning-based screen. Eur J Med Chem. 2022, 244:114803.

3. Dou X#, Sun Q#, Xu G#, Liu Y, Zhang C, Wang B, Lu Y, Guo Z, Su L, Huo T, Zhao X, Wang C, Yu Z, Song S, Zhang L, Liu Z, Lai L*, Jiao N*. Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease. Eur J Med Chem. 2022, 238:114508.

4. Sun Q#, Ye F#, Liang H#, Liu H#, Li C, Lu R, Huang B, Zhao L, Tan W*, Lai L*. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021, 6(1):212.

5. Liu H#, Ye F#, Sun Q#, Liang H#, Li C#, Li S, Lu R, Huang B, Tan W*, Lai L*. Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro. J Enzyme Inhib Med Chem. 2021, 36(1):497-503.

6. Sun Q#, Zhou T#, Xi D, Li X, Lü Z, Xu F, Wang C, Niu Y*, Xu P*. Design and synthesis of tripeptidyl furylketones as selective inhibitors against the β5 subunit of human 20S proteasome. Eur J Med Chem. 2020, 192:112160.

7. Liu P#, Liu H#, Sun Q#, Liang H, Li C, Deng X, Liu Y*, Lai L*. Potent inhibitors of SARS-CoV-2 3C-like protease derived from N-substituted isatin compounds. Eur J Med Chem. 2020, 206:112702.